Analysts Offer Insights on Healthcare Companies: Taro Pharma (TARO) and Viking Therapeutics (VKTX)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Taro Pharma (NYSE:TARO) and Viking Therapeutics (NASDAQ:VKTX) with bullish sentiments.

Taro Pharma (TARO)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Taro Pharma, with a price target of $120. The company’s shares closed on Friday at $98.30, close to its 52-week low of $93.01.

Selvaraju noted:

“Valuation methodology, risks and uncertainties. We ascribe a price objective of $120 per share, based on a forward EPS multiple of 15.7x applied to our current fiscal 2019 EPS forecast of $7.65 per share.”

According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 7.6% and a 45.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Synergy Pharmaceuticals Inc.

Currently, the analyst consensus on Taro Pharma is a Moderate Buy with an average price target of $120.

See today’s analyst top recommended stocks >>

Viking Therapeutics (VKTX)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics, with a price target of $31. The company’s shares closed on Friday at $17.42.

Pantginis noted:

“Valuation and risks to price target achievement. We reiterate our Buy rating and are increasing our price target to $31 from $28. The primary drivers to our valuation change include: (1) adjustment to share count off of recent equity raise (negative impact); recall we also base our valuation off of fully diluted share count; (2) increasing our projected chance for (3) increasing our projected peak sales for VK5211 to $1.65 billion from $1.1 billion. Our peak sales estimates are based on our U.S.”

According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.7% and a 39.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $31.75, representing an 82.3% upside. In a report issued on September 18, Maxim Group also maintained a Buy rating on the stock with a $28 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VKTX:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts